LifeScience Alley Launches 2012 Conference Registration

LifeScience Alley Launches 2012 Conference Registration

LifeScience Alley

[email protected]

Today, LifeScience Alley opens registration for its 2012 Conference: Today's Science. Tomorrow's Healthcare. This year's conference will be held on Dec. 5, 2012, at the Minneapolis Convention Center and features an updated program focused on bridging the gap between life science therapy developers and the rapidly evolving health care delivery system.

The day's events will include plenary keynote addresses, interactive breakout sessions, a new technology showcase and an exhibit hall redesigned to facilitate resource identification and networking. During the conference, attendees will have access to a new mobile event guide, which houses the event schedule, speaker biographies and networking tools. Also new this year is the opportunity to connect with attendees pre-conference at the Minnesota Warm-Up Reception on Dec. 4.

This year's keynote speakers include a variety of seasoned professionals with a vision for health care innovation. Dr. Veronique Roger, chair of Health Sciences Research at Mayo Clinic, is leading a keynote session entitled "From Strategy to Execution - Think Big. Start Small. Act Fast." Julie McHugh, COO of Endo Health Solutions, will be delivering an address titled "Owning the Care Pathway – A Redefined Healthcare Model."

LifeScience Alley is also taking a fresh approach to its interactive seminars this year, decreasing the number of options in order to increase depth and relevancy for all attendees.

"We want to provide insights on a smaller number of life science topics, but dig into them more deeply and increase the level of applicability in each sector of the life sciences," says Liz Rammer, COO at LifeScience Alley. This year's event will feature topics like big data, the new health care customer, neurological therapy development and accessing foreign capital.

In addition to standard exhibit booths, 10 organizations from around the country will be selected to display a novel or innovative technology in this year's New Technology Showcase. The selected technologies will represent a significant potential market impact and will reduce health care costs in medical devices, biologics and pharmaceuticals, health IT and health care delivery. Applications for the showcase are being accepted through July 31, 2012.

Online registration for this year's Conference and the New Technology Showcase application are available at .

The largest gathering of life science and health care industry professionals in the Midwest, LifeScience Alley's conference brings together global leaders in the industry to share vital knowledge, resources and practices necessary to innovate more effectively, meet evolving clinical and customer needs and better position businesses to succeed. This event includes participants from over 650 organizations worldwide and showcases novel life science technologies and student research. For more information, visit .

LifeScience Alley is an international leader in sharing best practices and is the largest state-based life sciences trade association in the United States. With a 26-year track record of providing valuable services and results-oriented outcomes to its members, LifeScience Alley enables business success through educating workforces, influencing state and federal public policy, supporting advancement in research and technological innovation and fostering industry connections. The Association's membership employs approximately 250,000 Minnesotans and its reach extends throughout the Midwest and Canada. Through a strategic affiliation, LifeScience Alley partners with The BioBusiness Alliance of Minnesota to strengthen the regional economy by assisting in the growth of established and emerging industries, and attracting new companies, talent and capital. For more information, visit .

Suggested Articles

NGM's aldafermin beat placebo at reversing liver scarring and inflammation, as well as reducing liver fat buildup in a 78-patient study.

The agreement sees Grifols waive a $32 million debt and pay $3 million in cash to take full ownership of three assets.

Astellas’ Xospata and Novartis’ Rydapt may help treat lung cancer that has grown resistant to EGFR inhibitors, researchers discovered.